Changes in bone density and turnover after alendronate or estrogen withdrawal.

@article{Wasnich2004ChangesIB,
  title={Changes in bone density and turnover after alendronate or estrogen withdrawal.},
  author={Richard D. Wasnich and Yu Zhao Bagger and David Hosking and Michael R Mcclung and Mei Wen Fiona Wu and Ann Marie Mantz and John Yates and Philip D. Ross and Peter Alexandersen and Pernille Ravn and Claus Christiansen and Arthur C. Santora},
  journal={Menopause},
  year={2004},
  volume={11 6 Pt 1},
  pages={622-30}
}
OBJECTIVE To compare bone mineral density (BMD) and bone turnover changes after therapy withdrawal in postmenopausal women treated with alendronate or estrogen-progestin. DESIGN In this randomized, blinded, multinational, placebo-controlled trial, 1,609 healthy postmenopausal women ages 45 to 59 years were assigned to receive alendronate, placebo, or open-label estrogen-progestin (conjugated equine estrogens plus medroxyprogesterone acetate or a cyclic regimen of 17 beta-estradiol… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

Similar Papers

Loading similar papers…